Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Published
Published
Guidance, NICE advice and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Last updated date
Last updated date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (60)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (1)
Diagnostics guidance (2)
Health technology evaluations (1)
Interventional procedures guidance (3)
NICE guidelines (1)
Technology appraisal guidance (60)
Apply filters
Showing 21 to 30 of 60
Sort by
Date
Title
Apply sorting
lung cancer
Remove lung cancer filter
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Published guidance, NICE advice and quality standards
Title
Reference number
Published
Last updated
Brigatinib for ALK-positive advanced non-small-cell
lung cancer
that has not been previously treated with an ALK inhibitor
TA670
27 January 2021
27 January 2021
Durvalumab in combination for untreated extensive-stage small-cell
lung cancer
(terminated appraisal)
TA662
25 November 2020
25 November 2020
Nivolumab for advanced squamous non-small-cell
lung cancer
after chemotherapy
TA655
21 October 2020
21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell
lung cancer
TA653
14 October 2020
14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell
lung cancer
TA654
14 October 2020
14 October 2020
Entrectinib for treating ROS1-positive advanced non-small-cell
lung cancer
TA643
12 August 2020
12 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell
lung cancer
TA638
1 July 2020
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell
lung cancer
(terminated appraisal)
TA635
30 June 2020
30 June 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell
lung cancer
TA628
13 May 2020
13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell
lung cancer
(terminated appraisal)
TA618
15 January 2020
15 January 2020
Previous page
1
2
Current page
3
4
5
6
Page
3
of
6
Next page
Results per page
10
25
50
All
Back to top